X.X the the provide our a review about and In ended Once to XXth everyone. you, for period I'll conference done remarks to June, results today, that, past at Good I've XXXX. our our Michael. strategy call Thank over company, Abcam. morning hand and implementation will to overview welcome talk Welcome my brief of good afternoon, Tommy, over and team years. I the the prepared of interim
measures for to work improve us and, faster, sustainability is health ultimately, all. achieve to enable to mission for their and Our researchers their mission
We make industry researchers working an day on inform works, to some life who on to view science each how trying might are biology impact the our that or disease are motivated understand aspect life discovery in the reproducible customers quality. science on highly or every highly our specific focus highest first delighting with important of time results sensitive, We care health systems. products time. the of systems how We enable
customer, We are is mission, for accelerating discovery see outcomes research that the their too, to one who for as quote these of are disease. using of the of you'll that learning in our be excited believe with this products to translation the from improvements are Customers stratify biopharma enabling also pace discoveries global in Abcam's well-known from to we research neurodegenerative clinical patients patients. biomarker
to Slide X. Turning
shown business have discovery their and whom of world, year, left. the and know supporting and the life range As helping of in research has market biological Abcam can the worldwide, market billion within we applied brand. who The strength we company needs. think and market, wide been support of an about Most Abcam's and protein the last our we of decisions $X all continue how the speed on roughly science we our the are and as around effectiveness researchers on gain influence share core and needs across products will discovery addressable the and about our products basic think XXX,XXX activity. a There purpose, depending stage our history of the services purchased are in to
partnership high of a sure win relationship Fox in organizations established partnerships this disease. that that focused fund eradicate the Foundation J. for and to with for also with we type long-standing the have common are One certain works quality, generate Michael direct disease how is of with can broader underpinning on areas. therapeutic clinical the and foundation be research a This to have us advanced applications. we theme research in results example is We The reproducible market. Parkinson's of their scale tools understanding
we are expanded As business to beyond clinical downstream take evolved, customers to in markets. serve seek has active biology These discovery. primarily discoveries they in further application have our as to translational customers
volumes customers capabilities create needs management to to systems early and for going their help customers such are larger health. Here, pursue and as Abcam further products human downstream Their looking recombinant projects build clinical encouraged to discovery take have relevant antibodies, improving production into applications. quality
At Abcam Finally, products customers best applications. present, available vitro to for and there we make than in look for content instances patient course more determine action care. technology of our are diagnostic XXX where will to using are the
Turning that see as the that of we foundation to can Abcam. research you With Slide core. expanded from historic into evolution of primary reseller end a antibodies X, have our the market,
extensions areas possible our and product are tuck-in addressable As I enabling focused growth. At a we it X markets, through and including greater to product share. wallet of coming market, or Capital lines, drive largely kits, few conjugation, adjacencies high-growth revenue to learned our a from engineered steady described which antibodies making These growth market gaining we of acquisitions whilst to earn our from would capabilities years, made serve served them. developed growth. customers, November XXXX the Day, recombinant for into just where capabilities leading labeling, Markets over and through us we and cell Abcam are ELISA protein our share new a have are in been these adjacencies on Investments our of expansion have customers we building expand pursue combination examples us
in the life current customers Slide on shown the serve and X, business capabilities to As downstream further products allows value science chain. Abcam's
they transition other as for discovery applications. drug is optimizing the assay One up of make pain and screening changing to lead and optimization identification time to early points the reagents spend customers on discovery the they from significant target working development,
and biotech to and described. just in X transitions our of the these mix. from for seen transformation Slide less we industries. the a product change portfolio have services products XXXX, significant pharmaceutical We are From capabilities, and building a illustrates XXXX changes make I've arising dramatic costly that of that portfolio these faster
are growth continues products of the our and a engineering antibodies, While revenue share our is most market The substantially from to in cell Focused strategic of strategic preparation as gain. expanded and growth has third-party business primary described. in I contributing proteins, a evolution portfolio, been, in core focused the we to china products. most recent supplier revenue of be and and our company Asia. growth growth our and change United our and designed to still in sample product to our considerable company, of market investments from assays, That's added innovator our that global the United has the Over life XX% derives Kingdom the the science and the represents come Southeast fairly States, manufactured majority we at and we in-house and Geographically, of activity. our beyond breadth revenues into mix biggest founding broadened believe from products Abcam.
investments in to our us innovation our led quality have and Finally, diversify customer mix.
mostly experience Markets do innovation see and, it business academic XXX the where to now the customer our X, the plan had that to biopharma, for was investment in mix target. the footprint determined volume here, end described our to enhance double development progress million. to On IT biopharma e-commerce to goals expand sales to that you we make operational the could, on But Day, improve broad us what customers. and you new higher-growth constraints significant remove as possible We nearly and ambitious our XXXX proposition with of see At strategy. accelerate GBP platforms, customers. heritage product Our Capital includes achieve our our acquire in Slide were sales presented and segment to we increase to we revenues capabilities to capacity, better our small to
planned global Looking most we back product over and X We've of infrastructure milestones globally. X.X completed years, XX% expected. and the This the new resulting the and as this to the footprint U.K. China increased and supply the years, have the our chain by logistics manufacturing beyond achieved past in investments with growth development ongoing over last support our buildup to capacity in U.S. of includes revenue
profitable we revenue future. for phasing antibodies have certainly development to growth created in capital its expected Things from increasing durable in the gone and product capabilities. that as But strategically share enable leadership development, will XX. and and portfolio We have thereby new deployed Slide we're our confident the our research COVID smoothly XXXX. increased investments implementation always product and in not financial to these we shown and in changed gain as in hoped sustain research expand our have continues investment M&A, strategic have as Abcam prudently market plan us challenges might we completed
CiteAb since the grown basis in XXXX. citations Our share of over XXX has by points database
to product development on dividends key pay for continues focus our Our stakeholders. in-house and has
in-house, antibody service important in is XX,XXX brand chain quality reputation. deliver made now higher to products. We and Our can supply other control customers, the portfolio our and full improving levels our recombinant Abcam words, thereby by over
to XX. Slide Let's move
our gains within market. into continues share Our our expansion core support from adjacencies growth newer addressable to
since growth cell engineered of protein XX% of XXXX. drivers over growth, with Assays, annualized compound an and have rate annual lines been key
make have We we chemistry capabilities, conjugation progress strengthened our expanding continue to our and catalog.
to this or growth, us expanded report a into sales. is over of further supporting we netosis, more pathways, company, years to product that Slide platform we've work, Europe diagnostic With a needed in novel response for of we this the to development the case from a path antibodies as hopeful Abcam. scalable products to can Abcam of products provided of financial and customer diagnosis shares monitoring through Volition where already inflammatory achieving basic single of Volition, earlier. body's and through one United remove both example is to catalog as transition to innovative that thousands real-world product success. against our condition. their digital materially the focused accelerate share multinational approach advantage for success, and validation our customer contributes footprint in customers underlying The a clinical an novel stories customer clinical are and The detecting on no antibodies our in are clinical access successful. pleased available website. X are States. the undertaken rising introductions which to that and account discover Volition's now cancer We a a success FDA we Volition Whilst highly making Abcam past of that research its the move to antibodies an that one describes Having mentioned epigenetics biomarkers natural constraint were to continue validated of that want operational in nucleosomes is part moves chose clinical within they new the to researchers primarily to Slide hundreds is these To Abcam's level of XX together human there's example, Volition on like mission. IVDR are immediate a regulatory we've as XX partner.
business these Abcam. take We the more path to the we transition and now XX proud continue experience a the step Both a are Slide to But What that from our customer digital for as we've that underway an legacy in and of data. at just replacing systems potential the e-commerce upon the got taken business will of to more year. I'm we're us years of e-commerce remains final ago. future. later has XX, improve is systems. this make to Most have of company updated place establishing place, On platform, recently built over upgrade the also and distribution and experience sales legacy bring innovation better and that the our our systems give
team an employees. We dedicated of have and extraordinary
We and for focused to and capabilities right on have success. building energy and the our the our right through talent hiring maintaining our adding retaining culture
employer again top once pleased Glassdoor. Kingdom by the United in are recognized be We to as a
Our our and sauce people Abcam's are they success. really secret drive
lockdown team together to in this Nowhere China. worked as those than our true team and the I during everyone tribute with was difficult one special months the recent Shanghai, China during more COVID throughout who pay lockdowns in
on on diversity inclusion our Abcam are employer, making progress agenda. continue we making to an We focus and inclusive and
example, of launched key across employee For of we've and interest, employee Head areas Inclusion. and X we've our first groups Diversity resource hired
this impact Finally, that highlighted ESG, environmental, first and efforts year. released social our our we're earlier governance by report pleased
XX it Slide over I review to with where to today. handing Before brief of stands on a Michael, Abcam conclude want
operating market-leading margins. the durable with will to built enabling a foundation strong our enable and sciences have products This bring We global strategy company high-quality is life organic growth time. to first reproducible every The innovation generate scientific capabilities. time of outcome us results
Finally, meeting the weeks, this only spoken call to for on Based we kind leaving our us delisting Thank recent over today. NASDAQ. in our listing general overwhelming extraordinary to their in support, November from I'll we've AIM U.K., in to it shareholders top Michael. on with your about the to you of now many an process. plan attention approve pass market
